TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38648814
Drug: Placebo (saline;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline; matched dosing regimen)
Study: 38648863
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg linzagolix with add-back therapy (ABT)
Study: 38648863
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg linzagolix alone
Study: 38649069
Drug: Heparin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (10 IU/mL and higher)
Study: 38649096
Drug: Dietary docosahexaenoic
Normalized name: docosahexaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary docosahexaenoic acid (DHA); specific dosage and duration not mentioned.
Study: 38649279
Drug: Volume-derived positron-emission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume-derived positron-emission tomography (PET) parameters assessed 6-8 weeks after the start of immune checkpoint inhibitors (ICPIs)
Study: 38649522
Drug: Shorter ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Shorter ocrelizumab infusion (2-h)
Study: 38649522
Drug: Conventional ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conventional ocrelizumab infusion (3.5-h)
Study: 38649595
Drug: Rilematovir (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilematovir (low or high dose)
Study: 38649826
Drug: Intermediate cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate cervical plexus block (IC) with 15 ml of bupivacaine 0.25% administered to each side
Study: 38649826
Drug: Cervical erector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical erector spinae block (ES) with 15 ml of bupivacaine 0.25% administered to each side at the C6 level
Study: 38649867
Drug: Concentrated vaccine-specific
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated vaccine-specific IgGs purified from sera
Study: 38649937
Drug: ICG-guided targeted
Normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-guided targeted laser (IGTL) combined with intravitreal injections (IVI) of anti-VEGF
Study: 38649937
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections (IVI) of anti-VEGF solely
Study: 38650037
Drug: Tislelizumab plus
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab plus lenvatinib (tislelizumab 200 mg every three weeks plus lenvatinib 12 mg for bodyweight ≥ 60 kg or 8 mg for bodyweight < 60 kg once daily)
Study: 38650039
Drug: Early progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early progressive resistance exercises (weekly supervised physiotherapy sessions and home exercises)
Study: 38650055
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day edoxaban for 12 months
Study: 38650055
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day edoxaban for 12 months
Study: 38650075
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) treatment for 6 months postoperatively
Study: 38650075
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no PEMF treatment)
Study: 38650969
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers and Oxandrolone (BBOX)
Study: 38651107
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BoNT-A) injection, specifically abobotulinumtoxinA, median total dose 500 units, injected into biceps brachii (83.3%), flexor carpi radialis (72.9%), and flexor digitorum profundus (66.7%).
Study: 38652564
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy initiation (ARTi)
Study: 38652564
Drug: Acute antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute antiretroviral therapy initiation (ARTi)
Study: 38652666
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for all patients
Study: 38652691
Drug: Brief intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intervention including enhanced communication skills, goal setting, safer sex behaviors, drug refusal skills, and life satisfaction.
Study: 38652978
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate variability biofeedback (HRV-BF) training sessions in addition to pharmacological standard therapy
Study: 38652978
Drug: Standard therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapies for 10 weeks (Control group)
Study: 38652999
Drug: Cenobamate 100
Normalized name: cenobamate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 100 mg/day
Study: 38653508
Drug: Epirubicin (3.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (3.75, 7.5 or 15 mg/m2)
Study: 38653618
Drug: Empagliflozin 25mg
Normalized name: EMPAGLIFLOZIN 25MG TAB
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 25mg once daily for three months
Study: 38653618
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily for three months
Study: 38653808
Drug: Acacia fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acacia fiber (AF) 10 g
Study: 38653808
Drug: Probiotic Bifidobacterium
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Bifidobacterium Lactis (BLa80) 4 g
Study: 38653903
Drug: iGlarLixi (Suliqua)
Normalized name: Ceratonia siliqua whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlarLixi (Suliqua) administered once daily
Study: 38653979
Drug: rAAV2/8-hCYP4V2 gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV2/8-hCYP4V2 gene therapy (single unilateral subretinal injection of 7.5 × 10^11 vg)
Study: 38653983
Drug: Umbilical cord-derived
Normalized name: Allogenic umbilical cord-derived mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord-derived mesenchymal stem cells (UC-MSCs) administered at escalating doses of 0.5 × 10^6 cells/kg.
Study: 38654329
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) provided by general practitioners or general practice staff after a 2-day PST course
Study: 38654416
Drug: Highly effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly effective disease-modifying therapy
Study: 38654416
Drug: Moderately effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately effective disease-modifying therapy
Study: 38654416
Drug: Overall disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall disease-modifying therapy exposure
Study: 38654422
Drug: Vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 10 mg once daily for 24 weeks
Study: 38654422
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg once daily for 24 weeks
Study: 38654422
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg once daily for 24 weeks
Study: 38654422
Drug: Vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 10 mg at 12 weeks
Study: 38654422
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg at 12 weeks
Study: 38655676
Drug: NTHi vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTHi vaccine antigens
Study: 38655842
Drug: TAF/EVG inserts
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF/EVG inserts (20 mg/16 mg) administered rectally
Study: 38655990
Drug: Probiotic drink
Normalized name: CVS Probiotic Drink Mix 10 Billion CFU Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic drink containing Actiregularis strain (5×106 cfu/ml) added to maternal diet once daily for 15 days
Study: 38655998
Drug: Rocuronium priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium priming (10% of the rocuronium dose administered 3 min before induction)
Study: 38656229
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone antagonist degarelix
Study: 38656355
Drug: Aronia melanocarpa
Normalized name: ARONIA MELANOCARPA FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aronia melanocarpa extract (AME) 180 mg anthocyanins/day
Study: 38656557
Drug: Alpibectir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpibectir (0.5 to 40 mg) administered as single daily doses in fasted and fed conditions.
Study: 38656557
Drug: Alpibectir (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpibectir (5 to 30 mg) administered once daily for 7 days in multiple ascending doses.
Study: 38656557
Drug: Alpibectir under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpibectir under fed conditions (10 mg).
Study: 38656557
Drug: Alpibectir (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpibectir (various doses) in multiple ascending doses.
Study: 38656736
Drug: BI 1358894
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1358894 (200 mg)
Study: 38656736
Drug: BI 1358894
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1358894 (50 mg and 100 mg)
Study: 38657084
Drug: MVA-BN-Filo, Ad26.ZEBOV
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-BN-Filo, Ad26.ZEBOV administered 14 days apart (n = 79)
Study: 38657084
Drug: Ad26.ZEBOV, MVA-BN-Filo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV, MVA-BN-Filo administered 28 days apart (n = 322)
Study: 38657084
Drug: Both vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccine regimens (14-day and 28-day)
Study: 38657201
Drug: Teclistamab (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab (1.5 mg/kg)
Study: 38657730
Drug: Sublingual Buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Buprenorphine with taper
Study: 38657730
Drug: Extended-release Buprenorphine
Normalized name: Buprenorphine Extended-Release Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release Buprenorphine with taper
Study: 38657999
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) treatment with moisturising cream, performed at 630 nm two times per week in palmoplantar areas (4 J/cm²)
Study: 38657999
Drug: Sham PBM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham PBM treatment with moisturising cream
Study: 38658012
Drug: Perioperative diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative diabetes treatment
Study: 38658024
Drug: Pamiparib, Tislelizumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib, Tislelizumab, Bevacizumab, and Nab-Paclitaxel (biomarker-driven combinatorial therapies)
Study: 38658392
Drug: Novel PSMA-targeting
Normalized name: Gallium-68 PSMA
DrugBank: Gallium-68 PSMA (DB16303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel PSMA-targeting radionuclide therapy agents
Study: 38658485
Drug: Anti-TNFα agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNFα agents
Study: 38658485
Drug: Anti-TNFα agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNFα agents (top 40% effect score distribution)
Study: 38658877
Drug: Psilocybin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (2 mg and 5 mg)
Study: 38659046
Drug: LCAR-B38M CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCAR-B38M CAR T-cell therapy
Study: 38659046
Drug: Subsequent therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent therapies after PD
Study: 38659187
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) oxygenation at flow rates of 50-60 L/min
Study: 38659334
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg up to once per day as EOD + PRN for 12 weeks
Study: 38662320
Drug: Ganglionic local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganglionic local opioid analgesia (GLOA) at the superior cervical ganglion with a total volume of 2 ml injected into the parapharyngeal space and its 'medial compartment'.
Study: 38662364
Drug: Postoperative pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative pelvic radiation using hypofractionated IMRT with 40 Gy in 16 fractions combined with concurrent chemotherapy
Study: 38662372
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg IV, max 1000 mg)
Study: 38662372
Drug: Modified higher-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified higher-dose regimen of abatacept
Study: 38662779
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOAC) adherence measured over 95 days
Study: 38662779
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOAC) adherence for hemorrhagic events
Study: 38662779
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOAC) adherence for ischemic events
Study: 38662979
Drug: Vidofludimus calcium
Normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidofludimus calcium 10 mg
Study: 38662979
Drug: Any dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any dose of vidofludimus calcium
Study: 38662991
Drug: ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibrutinib 560 mg and venetoclax 400 mg once daily
Study: 38662991
Drug: Elective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective treatment interruption (ETI) for patients in MRD-negative CR
Study: 38662991
Drug: Time-to-treatment failure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-to-treatment failure (TTF)
Study: 38662991
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with venetoclax-ibrutinib
Study: 38663539
Drug: Levonorgestrel 1.5
Normalized name: levonorgestrel 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 1.5 mg (LNG1X)
Study: 38663539
Drug: Levonorgestrel 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 3.0 mg (LNG2X)
Study: 38663539
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate 30 mg (UPA)
Study: 38663582
Drug: Individualised, escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised, escalated fraction dose of radiotherapy (24 x 3.0-5.4 Gy) with either sequential or concurrent chemoradiotherapy, or radiotherapy only.
Study: 38663582
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified in detail, but implied to be standard treatment without dose escalation).
Study: 38663950
Drug: Total carrageenans
Normalized name: Carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total carrageenans (100 mg per day)
Study: 38663950
Drug: Carrageenans gum
Normalized name: Carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrageenans gum (E407, 100 mg per day)
Study: 38663950
Drug: Tripotassium phosphate
Normalized name: dipotassium
DrugBank: Dipotassium phosphate (DB09414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium phosphate (E340, 500 mg per day)
Study: 38663950
Drug: Acetyl tartaric
Normalized name: Tartaric Acid
DrugBank: L-tartaric acid (DB09459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetyl tartaric acid esters of monoglycerides and diglycerides of fatty acids (E472e, 100 mg per day)
Study: 38663950
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (E331, 500 mg per day)
Study: 38663950
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (E412, 500 mg per day)
Study: 38663950
Drug: Gum arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum arabic (E414, 1000 mg per day)
Study: 38663950
Drug: Xanthan gum
Normalized name: Xanthan Gum
DrugBank: Xanthan gum (DB11253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthan gum (E415, 500 mg per day)
Study: 38664766
Drug: MTX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX plus corticosteroids (5 mg/m2 methotrexate)
Study: 38665252
Drug: Combination naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination naltrexone (NTX) and oral bupropion (BUP)
Study: 38665302
Drug: Mango Leaf
Normalized name: mango leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mango Leaf Extract (MLE) 300 mg
Study: 38668005
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care foams
Study: 38668005
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care spray
Study: 38668005
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no oral care product)
Study: 38669053
Drug: Avelumab 800
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 800 mg + chemotherapy (cisplatin + gemcitabine)
Study: 38669053
Drug: Avelumab 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab 1,200 mg + chemotherapy (cisplatin + gemcitabine)
Study: 38669053
Drug: Avelumab 800
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 800 mg + chemotherapy (carboplatin + pemetrexed)
Study: 38669053
Drug: Avelumab 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab 1,200 mg + chemotherapy (carboplatin + pemetrexed)
Study: 38669354
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of L9LS
Study: 38669354
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of L9LS
Study: 38669638
Drug: Erenumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab (140 mg once monthly for 3 years)
Study: 38669638
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by Erenumab (140 mg once monthly for 3 years)
Study: 38670599
Drug: Acyclovir therapy
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir therapy (specific dosage and duration not mentioned)
Study: 38671251
Drug: Remimazolam, bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam, bolus dose starting at 0.3 mg·kg
Study: 38671587
Drug: tislelizumab +
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tislelizumab + chemotherapy
Study: 38672531
Drug: Bortezomib addition
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib addition to standard chemotherapy
Study: 38675738
Drug: TAPCells-based vaccination
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAPCells-based vaccination therapy
Study: 38675784
Drug: CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac vaccine (Sinovac Biotech), administered to indigenous Brazilian individuals between February 2021 and June 2021.
Study: 38675784
Drug: CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac vaccine (Sinovac Biotech), administered to indigenous Brazilian individuals.
Study: 38676324
Drug: Electrical dry
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical dry needling and thrust manipulation plus multimodal physical therapy
Study: 39436270
Drug: Multimodal physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal physical therapy alone
Study: 38676659
Drug: Cat food
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cat food containing anti-Fel d 1 IgY antibodies
Study: 38676683
Drug: Divozilimab (DIV)
Normalized name: divozilimab
DrugBank: Divozilimab (DB18878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divozilimab (DIV) 500 mg
Study: 38676683
Drug: Teriflunomide (TRF)
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Teriflunomide (TRF) 14 mg
Study: 38677235
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy Intervention (FREE)
Study: 38677300
Drug: No antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiviral drugs
Study: 38677720
Drug: OP-724 intravenous
Normalized name: OP-1
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: OP-724 intravenous infusion at doses of 140 or 280 mg/m
Study: 38678093
Drug: R-HAD +
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-HAD + B (rituximab, high-dose cytarabine, dexamethasone with bortezomib)
Study: 38678093
Drug: R-HAD (rituximab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-HAD (rituximab, high-dose cytarabine, dexamethasone without bortezomib)